细胞疗法新药研发商Lyell Immunopharma同意收购ImmPACT Bio -动脉网

Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy

benzinga 等信源发布 2024-10-30 14:31



可切换为仅中文







Last week, Lyell Immunopharma Inc. LYEL agreed to acquire ImmPACT Bio USA Inc., a privately owned clinical-stage biotechnology company.

上周，莱尔免疫制药公司（Lyell Immunopharma Inc.）同意收购私人拥有的临床阶段生物技术公司ImmPACT Bio USA Inc。

Lyell has prioritized its pipeline to focus resources on its most differentiated CAR T-cell clinical programs, including IMPT-314 following the close of the acquisition and LYL119.

莱尔已优先考虑将资源集中在其最分化的CAR T细胞临床项目上，包括收购结束后的IMPT-314和LYL119。

Also Read: Lyell Immunopharma Shares Plunge On One Patient Death In CAR-T Cell Therapy Cancer Trial

另读：莱尔免疫制药（Lyell Immunopharma）在CAR-T细胞治疗癌症试验中因一名患者死亡而股价暴跌

Lyell announced the discontinuation of the development of LYL797 to focus on the Phase 1 clinical trial of LYL119, which is expected to initiate enrollment of patients with platinum-resistant ovarian cancer or relapsed/refractory endometrial cancer this year or early next year.

莱尔宣布停止开发LYL797，专注于LYL119的1期临床试验，预计今年或明年初将开始招募铂类耐药卵巢癌或复发/难治性子宫内膜癌患者。

The LYL845 tumor-infiltrating lymphocyte (TIL) program is also being discontinued, as the clinical data in patients with advanced melanoma did not meet pre-determined criteria for continued development.

LYL845肿瘤浸润淋巴细胞（TIL）计划也正在停止，因为晚期黑色素瘤患者的临床数据不符合预定的持续发展标准。

Its next-generation TIL and rejuvenation programs that are in preclinical development will also be discontinued.

其处于临床前开发阶段的下一代TIL和复兴计划也将停止。

Lyell expects its cash balance to fund operations into 2027.

莱尔预计其现金余额将为2027年的运营提供资金。

Deal terms include upfront consideration of $30 million in cash and 37.5 million Lyell shares.

交易条款包括3000万美元现金和3750万股莱尔股票的前期对价。

ImmPACT shareholders will also be eligible for contingent consideration consisting of 12.5 million Lyell shares and a low single-digit royalty on future net sales.

ImmPACT股东也将有资格获得或有对价，包括1250万股莱尔股份和未来净销售额的低个位数版税。

BofA Securities has downgraded Lyell from Buy to Underperform, with a price target of $1, down from $6.

美国银行证券将莱尔的评级从买入下调为表现不佳，目标价格从6美元降至1美元。

The analyst said, “While discontinuation of ‘797 isn’t a surprise, we think optimism is growing for next-gen ‘119’s improved therapeutic window.”

这位分析师说：“虽然797年的停产并不令人惊讶，但我们认为对下一代119年改进的治疗窗口的乐观情绪正在增长。”

The acquisition of ImmPACT Bio for its IMPT-314 introduces complexities that could cloud the narrative. The analyst added that while the potential of ‘314 is visible, the program appears to lack clinical and commercial synergy, and with limited resources and rising competition, it risks becoming a distraction..

收购ImmPACT Bio的IMPT-314带来了可能掩盖故事的复杂性。这位分析师补充说，虽然314年的潜力是显而易见的，但该计划似乎缺乏临床和商业协同作用，而且由于资源有限和竞争加剧，它有可能成为一种干扰。。

An analyst noted that with Lyell's focus on restarting its solid tumor program and expanding into hematology, it's challenging to maintain a positive outlook.

一位分析师指出，随着莱尔专注于重新启动实体瘤项目并扩展到血液学领域，保持积极的前景具有挑战性。

It remains uncertain if IMPT-314 can provide significant clinical improvements, and it will likely face tough competition from established players like Gilead Sciences Inc GILD, Bristol Myers Squibb & Co BMY, and Novartis AG NVS.

IMPT-314是否能提供显着的临床改善尚不确定，它可能会面临来自吉利德科学公司GILD，百时美施贵宝公司BMY和诺华公司NVS等老牌公司的激烈竞争。

Price Action: LYEL stock is down 9.16% at $0.86 at last check Wednesday.

价格走势：莱尔股价周三最后一次下跌9.16%，至0.86美元。